COVID-19 Coronavirus Updates: Sunday / Monday, Jan. 9-10


United Kingdom:


The DARPin (Designed Ankyrin Repeat Protein) antiviral therapeutic candidate met the primary endpoint of viral load reduction over eight days in a study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep versus placebo, the two companies said in a statement.

The two secondary endpoints also showed a clinically meaningful benefit compared with a placebo, the partners said.

Novartis will first seek the approval from the U.S. Food and Drug Administration (FDA), where it is applying for an Emergency Use Authorization (EUA).

DARPins offer a differentiated approach to treating COVID-19 through a single molecule that can engage up to three parts of the SARS-CoV-2 virus simultaneously to neutralize the virus through multiple mechanisms, Molecular Partners said on its website…


The post COVID-19 Coronavirus Updates: Sunday / Monday, Jan. 9-10 appeared first on Balloon Juice.